{
    "SPADE_UN_14344": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_14344",
            "Peptide Name": "LP-72",
            "Source": "Synthetic construct",
            "Family": "Retroviridae",
            "Gene": "Not found",
            "Sequence": "VRYLEANIEELLKKAEEQQKKNEEELKKLEX",
            "Sequence Length": 31,
            "UniProt Entry": [
                "http://www.uniprot.org/uniprot/P03377"
            ],
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Antimicrobial",
                "Antiviral"
            ],
            "Target Organism": "[Ref.30089693]HIV-1 HXB2:inhibition of cell-cell fusion in TZM-bl cells(IC50=23±3 pM);HIV-1 NL4-3:inhibition of pseudovirus infection in TZM-bl cells(IC50=28±1 pM);HIV-1 JRCSF:inhibition of virus infection in TZM-bl cells(IC50=24±9 pM).",
            "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
            "Cytotoxicity": "No cytotoxicity information or data found in the reference(s) presented in this entry",
            "Binding Target": "membrane",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Acetylation",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C161H269N43O53",
            "Mass": 3784.51,
            "PI": 5,
            "Net Charge": -2,
            "Hydrophobicity": -1.4,
            "Half Life": "Mammalian:100 hourYeast:>20 hourE.coli:>10 hour",
            "Mechanism of action": "The peptide acts by binding to the heptad repeat 1 (HR1) region of gp41 and preventing the interaction of the HR1 and HR2 domains, which is required for virus–cell fusion.(By similar)",
            "Literature": [
                {
                    "Title": "Structural and Functional Characterization of Membrane Fusion Inhibitors with Extremely Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.",
                    "Pubmed ID": "30089693",
                    "Reference": "J Virol. 2018 Sep 26;92(20)e01088-18.",
                    "Author": "Chong H, Zhu Y, Yu D, He Y.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30089693"
                }
            ],
            "Frequent Amino Acids": "EKL",
            "Absent Amino Acids": "CDFGHMOPSTUW",
            "Basic Residues": 7,
            "Acidic Residues": 9,
            "Hydrophobic Residues": 10,
            "Polar Residues": 15,
            "Positive Residues": 7,
            "Negative Residues": 9,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_14368",
                    "Similarity": 1.0,
                    "Sequence": "VRYLEANIEELLKKAEEQQKKNEEELKKLEK"
                },
                {
                    "SPADE_ID": "SPADE_UN_14353",
                    "Similarity": 1.0,
                    "Sequence": "LEANIEELLKKAEEQQKKNEEELKKLEK"
                },
                {
                    "SPADE_ID": "SPADE_UN_14454",
                    "Similarity": 1.0,
                    "Sequence": "LEANIEELLKKAEEQQKKNEEELKKLE"
                }
            ]
        }
    }
}